反转录病毒介导的HSV-tk基因治疗大鼠脑胶质瘤的实验研究

Study of retrovirus mediated HSV tk gene therapy for rat glioma

目的：进行Ｃ６大鼠脑胶质瘤的基因治疗实验研究。方法：采用反转录病毒介导的基因转移和ＡＣＶ体内治疗方法进行研究。结果：构建了带有ＨＳＶ－ｔｋ基因的反转录病毒载体ＧＩＮａＴＫ，应用脂质体转移方法将ＧＩＮａＴＫ导入反转录病毒包装细胞ＰＡ３１７，成为产病毒细胞ＰＡ３１７ＴＫ，用带有ＨＳＶ－ｔｋ基因的复制缺陷型反转录病毒感染Ｃ６细胞，命名为Ｃ６ＴＫ细胞，对ＧＣＶ和ＡＣＶ的敏感性分别高于亲本４５０倍和１０倍；成功地建立了大鼠脑胶质瘤模型，并证实转染细胞Ｃ６ＴＫ的成瘤效应未改变，存活期约为１５天；而经ＡＣＶ治疗后，含有Ｃ６ＴＫ细胞的肿瘤生长明显被抑制，大鼠生存期延长为５７．８±８．０７天，尤其是采用ＰＡ３１７ＴＫ细胞混和治疗组和原位治疗组，肿瘤基本消失，大鼠生存期显著延长，混和治疗组存活１２０天以上，原位治疗组存活至７１．４±３６．１天。ｔ检验，Ｐ值均小于０．００１。结论：ＨＳＶ－ｔｋ／ＡＣＶ系统基因治疗大鼠脑胶质瘤疗效显著。

Objective: Study to the gene therapy for rat C6 glioma. Methods: Retroviral vector/ACV system were used. Results: GINaTK retroviral vector containing HSV tk was constructed and transduced into PA317 retrovirus packaging cell by lipofectin (named PA317TK). Rat glioma cell C6 was infected by the deficiency recombinant retrovirus (named C6TK). The sensitivity of C6TK cells to GCV or ACV increased 450 or 10 times than that of C6 cells respectively. Rat C6 glioma model was successfully built, and SD rats inoculated intracerebrally C6TK cells had normal gliomas. The average survival periods of the rats were about 15 days. However, after treated with ACV, the growth of C6TK tumors obviously regressed, and the survival periods extended to 57 8±8 1 days, especially in rats injected with mixed PA317TK and C6 cells or in situ PA317TK cells, which the tumors nearly disappeared after ACV administration and the survival periods extended to over 120 or 71 4±36 1 days respectively, P<0 001(t test). Conclusion: These results suggested that HSV tk/ACV system was effective in gene therapy for rat glioma.